CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Kyu Hwan | - |
dc.contributor.author | Kang, Min Ju | - |
dc.contributor.author | Suh, Jee Won | - |
dc.contributor.author | Pyun, Jung-Min | - |
dc.contributor.author | Ryoo, Nayoung | - |
dc.contributor.author | Park, Young Ho | - |
dc.contributor.author | Youn, Young Chul | - |
dc.contributor.author | Jang, Jae-Won | - |
dc.contributor.author | Jeong, Jee Hyang | - |
dc.contributor.author | Park, Kyung Won | - |
dc.contributor.author | Choi, Seong Hye | - |
dc.contributor.author | Suk, Kyoungho | - |
dc.contributor.author | Lee, Ho-Won | - |
dc.contributor.author | Ko, Pan-Woo | - |
dc.contributor.author | Lee, Chan-Nyoung | - |
dc.contributor.author | Lim, Tae-Sung | - |
dc.contributor.author | An, Seong Soo A. | - |
dc.contributor.author | Kim, SangYun | - |
dc.date.available | 2020-08-10T00:35:49Z | - |
dc.date.created | 2020-07-24 | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 1758-9193 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/76177 | - |
dc.description.abstract | BACKGROUND: Recently, several studies suggested potential involvements of α-synuclein in Alzheimer's disease (AD) pathophysiology. Higher concentrations of α-synuclein were reported in cerebrospinal fluid (CSF) of AD patients with a positive correlation towards CSF tau, indicating its possible role in AD. We analyzed the CSF biomarkers to verify whether α-synuclein could be an additional supported biomarker in AD diagnosis. METHODS: In this cross-sectional study, CSF samples of 71 early-onset AD, 34 late-onset AD, 11 mild cognitive impairment, 17 subjective cognitive decline, 45 Parkinson's disease, and 32 healthy control (HC) were collected. CSF amyloid-β1-42 (A), total tau (N), and phosphorylated tau181 (T) were measured by commercial ELISA kits, and in-house ELISA kit was developed to quantify α-synuclein. The cognitive assessments and amyloid-PET imaging were also performed. RESULTS: CSF α-synuclein manifested a tendency to increase in AD and to decreased in Parkinson's disease compared to HC. The equilibrium states of total tau and α-synuclein concentrations were changed significantly in AD, and the ratio of total tau/α-synuclein (N/αS) was dramatically increased in AD than HC. Remarkably, N/αS revealed a strong positive correlation with tau phosphorylation rate. Also, the combination of N/αS with amyloid-β1-42/phosphorylated tau181 ratio had the best diagnosis performance (AUC = 0.956, sensitivity = 96%, specificity = 87%). In concordance analysis, N/αS showed the higher diagnostic agreement with amyloid-β1-42 and amyloid-PET. Analysis of biomarker profiling with N/αS had distinctive characteristics and clustering of each group. Especially, among the group of suspected non-Alzheimer's disease pathophysiology, all A-T+N+ patients with N/αS+ were reintegrated into AD. CONCLUSIONS: The high correlation of α-synuclein with tau and the elevated N/αS in AD supported the involvement of α-synuclein in AD pathophysiology. Importantly, N/αS improved the diagnostic performance, confirming the needs of incorporating α-synuclein as a biomarker for neurodegenerative disorders. The incorporation of a biomarker group [N/αS] could contribute to provide better understanding and diagnosis of neurodegenerative disorders. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.relation.isPartOf | Alzheimer's research & therapy | - |
dc.title | CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylation | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000552835800001 | - |
dc.identifier.doi | 10.1186/s13195-020-00648-9 | - |
dc.identifier.bibliographicCitation | Alzheimer's research & therapy, v.12, no.1, pp.83 - 95 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85088016172 | - |
dc.citation.endPage | 95 | - |
dc.citation.startPage | 83 | - |
dc.citation.title | Alzheimer's research & therapy | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | An, Seong Soo A. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Alzheimer’s disease | - |
dc.subject.keywordAuthor | Biomarker | - |
dc.subject.keywordAuthor | Cerebrospinal fluid | - |
dc.subject.keywordAuthor | Tau | - |
dc.subject.keywordAuthor | α-Synuclein | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.